长春高新“治疗男童发育不良新药”引爆股价，公司回应

Group 1 - The core point of the article highlights that Changchun High-tech's stock price continues to rise, with a weekly increase of over 12% following the approval of its subsidiary GenSci's clinical trial application for GenSci 141 ointment, the world's first drug targeting pediatric micropenis, although the project is still in its early stages [1] - In recent years, Changchun High-tech has faced pressure on its performance, with a projected net profit decline of over 90% by 2025, as the company is undergoing a transformation and diversifying into multiple fields [1] - In December of the previous year, GenSci's subsidiary signed an exclusive licensing agreement, but the related revenue is not expected to be recognized until the 2025 fiscal year, which has not improved the company's performance [1]